Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) had its price target increased by investment analysts at HC Wainwright from $115.00 to $120.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target would indicate a potential upside […]

Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) had its price objective cut by equities researchers at Guggenheim from $43.00 to $35.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Guggenheim’s price objective indicates a potential upside of 39.89% from the company’s current price. Other […]

Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price objective lifted by Cantor Fitzgerald from $750.00 to $795.00 in a research report sent to investors on Friday morning,Benzinga reports. Cantor Fitzgerald currently has an overweight rating on the biopharmaceutical company’s stock. Several other equities analysts also recently weighed in on REGN. Citigroup downgraded Regeneron Pharmaceuticals […]